Kansas City,
13
June
2018
|
07:03 PM
Europe/Amsterdam

Neurology Today: FDA Approved Erenumab, First CGRP Inhibitor, for Migraine

Dr. Jennifer Bickel, Chief of the Headache Section at Children's Mercy
"These antibodies offer the ability to target the migraine pathway in ways that we have never done before."
Dr. Jennifer Bickel, Chief of the Headache Section at Children's Mercy
By Fay Ellis

The US Food and Drug Administration (FDA) approved erenumab (Aimovig), the first in a new class of calcitonin-gene related peptide (CGRP) antagonists, for the prevention of migraine.

Erenumab, which is given by monthly injection, is one of four monoclonal antibodies that have been tested in large clinical trials that target or block CGRP, which is produced by trigeminal nerve endings and elevated during migraine attacks.

Jennifer Bickel, MD, FAAN, associate professor of pediatrics at Children's Mercy Hospital of the University of Missouri in Kansas City, highlighted the emergence of CGRPs as one of the most promising developments in 2017.

"These antibodies offer the ability to target the migraine pathway in ways that we have never done before," Dr. Bickel told Neurology Today. "In addition to demonstrating efficacy, these antibodies appear well tolerated without the sedation and mood changes that can limit the use of conventional migraine medications."

 

Read the full story via Neurology Today.

Learn more about Headaches and Kids: What Parents Need to Know.

Learn more about the Headache Treatment Center and Headache Relief Clinics at Children’s Mercy.